[HTML][HTML] Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions
CB Savelli, M Clerico, B Botto, C Secreto, F Cavallo… - Cancers, 2024 - ncbi.nlm.nih.gov
In the last decade, anti-CD19 CAR-T cell therapy has led to a treatment paradigm shift for B-
cell non-Hodgkin lymphomas, first with the approval for relapsed/refractory (R/R) large B-cell …
cell non-Hodgkin lymphomas, first with the approval for relapsed/refractory (R/R) large B-cell …
[HTML][HTML] Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions
C Benevolo Savelli, M Clerico, B Botto, C Secreto… - Cancers, 2023 - mdpi.com
Simple Summary Despite the impressive efficacy of chimeric antigen receptor-T (CAR-T) cell
therapy in the treatment of some subtypes of lymphomas, many patients are either not …
therapy in the treatment of some subtypes of lymphomas, many patients are either not …
New hopes in relapsed refractory primary central nervous system lymphoma
T Calimeri, C Steidl, P Fiore… - Current Opinion in …, 2023 - journals.lww.com
New hopes in relapsed refractory primary central nervous sys... : Current Opinion in Oncology
New hopes in relapsed refractory primary central nervous system lymphoma : Current Opinion …
New hopes in relapsed refractory primary central nervous system lymphoma : Current Opinion …